OncoMatch/Clinical Trials/NCT03818334
Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies
Is NCT03818334 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including Cyclophosphamide and ATG for bone marrow transplant complications.
Treatment: Cyclophosphamide · ATG — This study aims to evaluate the clinical efficacy of cyclophosphamide in patients receiving a bone marrow graft from a matched unrelated donor in overall survival, progression free survival and cumulative incidence of acute and chronic GvHD. Thirty patients will receive cyclophosphamide while twenty patients will receive antihuman T-lymphocyte immune globulin (ATG).
Check if I qualifyExtracted eligibility criteria
Performance status
HCT-CI 0–3
Prior therapy
Cannot have received: allogeneic bone marrow transplantation
Lab requirements
Kidney function
glomerular filtration rate < 50 mL.hour excluded
Cardiac function
heart ejection fraction < 45% excluded
Severe organic disfunction (heart ejection fraction < 45%, glomerular filtration rate < 50 mL.hour, pulmonary DLCO < 50%)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify